PMID- 19691587
OWN - NLM
STAT- MEDLINE
DCOM- 20091124
LR  - 20131121
IS  - 1476-4431 (Electronic)
IS  - 1476-4431 (Linking)
VI  - 19
IP  - 1
DP  - 2009 Feb
TI  - Coagulation effects of low molecular weight heparin compared with heparin in dogs 
      considered to be at risk for clinically significant venous thrombosis.
PG  - 74-80
LID - 10.1111/j.1476-4431.2008.00339.x [doi]
AB  - OBJECTIVE: Compare the effects of 3 anticoagulation protocols on anti-factor Xa 
      activity (AXa). DESIGN: Prospective, randomized, double-blind study. SETTING: 
      University veterinary teaching hospital. ANIMALS: Eighteen dogs considered to be 
      at risk for venous thrombosis. INTERVENTIONS: Each dog was randomly assigned to 1 
      of the following 3 groups (n=6/group) and was treated for 24 hours: low-dose 
      heparin (LDH), high-dose heparin (HDH), and dalteparin (DP). Dogs in the LDH 
      group received a constant rate infusion (CRI) of unfractionated heparin (UFH) at 
      300 U/kg/d, the HDH group received a bolus of 100 U/kg of UFH IV, then a CRI of 
      900 U/kg/day, and the DP group received 100 U/kg DP SC at 0, 12, and 24 hours. 
      MEASUREMENTS AND MAIN RESULTS: A total of 54 samples for activated partial 
      thromboplastin time (aPTT) and AXa assays were collected at 0, 4, and 28 hours. 
      Six samples had an AXa >0.1 U/mL, 5 of those were from the HDH group at hour 4. 
      Two samples from the HDH group at hour 4 had a prolonged aPTT (93 and 200 
      seconds) and the highest AXa (0.6 and 1.0 U/mL, respectively). Four additional 
      dogs in the HDH group did not complete the study due to hemorrhage; none of the 
      dogs completing the study showed signs of hemorrhage. CONCLUSIONS: Neither DP nor 
      LDH increased AXa to values considered therapeutic in humans (0.5-1 and 0.35-0.75 
      U/mL, respectively), and both protocols appear to be inadequate to increase AXa 
      in dogs with clinical illness. HDH increased AXa to this range in 2 of 6 dogs, 
      but had unpredictable effects on aPTT and resulted in hemorrhage in some dogs.
FAU - Scott, Kielyn C
AU  - Scott KC
AD  - Department of Clinical Sciences, Veterinary Teaching Hospital, North Carolina 
      State University, Raleigh, NC 27606, USA. kielyns@yahoo.com
FAU - Hansen, Bernie D
AU  - Hansen BD
FAU - DeFrancesco, Teresa C
AU  - DeFrancesco TC
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Vet Emerg Crit Care (San Antonio)
JT  - Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
JID - 101152804
RN  - 0 (Anticoagulants)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*therapeutic use
MH  - Dalteparin/administration & dosage/*therapeutic use
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Risk Factors
MH  - Venous Thrombosis/drug therapy/*veterinary
EDAT- 2009/08/21 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/08/21 09:00
PHST- 2009/08/21 09:00 [entrez]
PHST- 2009/08/21 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - VEC339 [pii]
AID - 10.1111/j.1476-4431.2008.00339.x [doi]
PST - ppublish
SO  - J Vet Emerg Crit Care (San Antonio). 2009 Feb;19(1):74-80. doi: 
      10.1111/j.1476-4431.2008.00339.x.